Bristol-Myers to combo Opdivo, Yervoy with AbbVie's Rova-T in next-gen cancer cocktail trials - FiercePharma

FiercePharma

Bristol-Myers to combo Opdivo, Yervoy with AbbVie's Rova-T in next-gen cancer cocktail trials FiercePharma Bristol-Myers Squibb's immunotherapy Opdivo has been powering ahead, racking up sales and new FDA approvals one after another. And with cancer-fighting immunotherapy cocktails seen as the next wave in oncology, the Big Pharma has teamed up with a ... AbbVie, Bristol-Myers to combine checkpoint inhibitors, Rova-T in cancer trialsFierceBiotech AbbVie, BMS Partner on Cancer Clinical CollaborationGenetic Engineering & Biotechnology News AbbVie (ABBV), Bristol-Myers Squibb (BMY) to Collaborate on Rova-T + Opdivo ComboStreetInsider.com BioPharma Dive -Seeking Alpha -Finance Daily all 7 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNEjoGeW2Cr78QPdhJWFt5KcHpWZxQ&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779167535367&ei=GjOWV6icDoy23gHJ5aSQCA&url=http://www.fiercepharma.com/marketing/bristol-myers-to-combo-opdivo-yervoy-abbvie-s-rova-t-next-gen-cancer-cocktail-trials
via IFTTT